Interim results from a phase I randomized, placebo-controlled trial of novel SARS-CoV-2 beta variant receptor-binding domain recombinant protein and mRNA vaccines as a 4th dose booster

BACKGROUND: SARS-CoV-2 booster vaccination should ideally enhance protection against variants and minimise immune imprinting. This Phase I trial evaluated two vaccines targeting SARS-CoV-2 beta-variant receptor-binding domain (RBD): a recombinant dimeric RBD-human IgG(1) F(c)-fusion protein, and an...

Descripción completa

Detalles Bibliográficos
Autores principales: Nolan, Terry M., Deliyannis, Georgia, Griffith, Maryanne, Braat, Sabine, Allen, Lilith F., Audsley, Jennifer, Chung, Amy W., Ciula, Marcin, Gherardin, Nicholas A., Giles, Michelle L., Gordon, Tom P., Grimley, Samantha L., Horng, Lana, Jackson, David C., Juno, Jennifer A., Kedzierska, Katherine, Kent, Stephen J., Lewin, Sharon R., Littlejohn, Mason, McQuilten, Hayley A., Mordant, Francesca L., Nguyen, Thi H.O., Soo, Vanessa Pac, Price, Briony, Purcell, Damian F.J., Ramanathan, Pradhipa, Redmond, Samuel J., Rockman, Steven, Ruan, Zheng, Sasadeusz, Joseph, Simpson, Julie A., Subbarao, Kanta, Fabb, Stewart A., Payne, Thomas J., Takanashi, Asuka, Tan, Chee Wah, Torresi, Joseph, Wang, Jing Jing, Wang, Lin-Fa, Al-Wassiti, Hareth, Wong, Chinn Yi, Zaloumis, Sophie, Pouton, Colin W., Godfrey, Dale I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10696466/
http://dx.doi.org/10.1016/j.ebiom.2023.104878

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10696466/
http://dx.doi.org/10.1016/j.ebiom.2023.104878

Ejemplares similares